Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy

Leukemia volume 20, pages 2172–2174 (2006)Cite this article

Despite advances in defining clinically relevant subtypes of diffuse large B-cell lymphoma (DLBCL), identifying high-risk patients and improved therapeutic options remains a priority. One approach is through the identification of tumor-associated antigens (TAAs), of which cancer testis antigens (CTAs) are of particular interest. Their restricted normal tissue expression, commonly widespread expression in tumors and immunogenicity makes them attractive therapeutic targets and markers for early diagnosis of cancer.1

We originally identified per ARNT SIM (PAS) domain containing 1 (PASD1) protein as a TAA in DLBCL2 and acute myeloid leukemia (AML).3 Circulating antibodies to this putative transcription factor were present in multiple high-risk DLBCL and AML patients.2, 3 The PASD1 gene maps to chromosome Xq28, a locus containing many CTA genes,1 and encodes two PASD1 transcripts, PASD1_v1 and PASD1_v2. In normal tissues, PASD1 mRNA was restricted to testis but its expression in DLBCL cell lines and solid tumors2 identified PASD1 as a candidate DLBCL-associated CTA. This is significant as CTAs are infrequently expressed in B-cell non-Hodgkin's lymphomas (NHLs).4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Simpson AJ, Caballero OL, Jungbluth A, Chen Y-T, Old LJ . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615–625.

    Article  CAS  Google Scholar 

  2. Liggins AP, Brown PJ, Asker K, Pulford K, Banham AH . A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. Br J Cancer 2004; 91: 141–149.

    Article  CAS  Google Scholar 

  3. Guinn B-A, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S et al. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 335: 1293–1304.

    Article  CAS  Google Scholar 

  4. Xie X, Wacker HH, Huang S, Regitz E, Preuss K-D, Romeike B et al. Differential expression of cancer testis genes in histological subtypes of non-Hodgkin’s lymphomas. Clin Cancer Res 2003; 9: 167–173.

    CAS  PubMed  Google Scholar 

  5. Kalejs M, Erenpreisa J . Review Cancer/testis antigens and gametogenesis: a review and ‘brain-storming’ session. Cancer Cell Int 2005; 5: 1–11.

    Article  Google Scholar 

  6. Jungbluth AA, Chen Y-T, Stockert E, Busam KJ, Kolb D, Iversen K et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92: 856–860.

    Article  CAS  Google Scholar 

  7. Sahota S, Goonewardena M, Cooper C, Liggins AP, Ait-Tahar K, Zojer N et al. PASD1 is a potential multiple myeloma associated antigen. Blood (in press).

  8. Vose J . Personalised immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Clin Adv Hematol Oncol 2006; 3: 923–932.

    Google Scholar 

Download references

Acknowledgements

This work is supported by grants from the Leukemia Research Fund (APL, KA-T, AHB, KP), Isis University Innovation Fund and the Julian Starmer-Smith Memorial Fund (CDOC). We are also grateful to the CNIO Tumor Bank Network.

Author information

Authors and Affiliations

  1. Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK

    C D O Cooper, A P Liggins, K Ait-Tahar, A H Banham & K Pulford

  2. Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

    G Roncador

Authors
  1. C D O Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A P Liggins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Ait-Tahar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Roncador
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A H Banham
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Pulford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Pulford.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooper, C., Liggins, A., Ait-Tahar, K. et al. PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia 20, 2172–2174 (2006). https://doi.org/10.1038/sj.leu.2404424

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404424

This article is cited by

Search

Advanced search

Quick links